Literature DB >> 2898148

The distribution of the incubation period for the acquired immunodeficiency syndrome (AIDS).

G F Medley1, L Billard, D R Cox, R M Anderson.   

Abstract

This paper contains details of methods and full results of estimates of the incubation period of acquired immunodeficiency syndrome (AIDS) that were outlined in a previous paper by Medley et al. (Nature, Lond. 328, 719 (1987)). The original model is modified to assess the influence of age and sex on the incubation period: age, but not sex, is statistically significant. The difficulties associated with interpretation of these data, and the additional information that would be required to resolve these difficulties are discussed.

Entities:  

Mesh:

Year:  1988        PMID: 2898148     DOI: 10.1098/rspb.1988.0026

Source DB:  PubMed          Journal:  Proc R Soc Lond B Biol Sci        ISSN: 0950-1193


  5 in total

1.  Risk factors for HIV seropositivity among people consulting for HIV antibody testing: a pilot surveillance study in Quebec.

Authors:  M Alary; J Castel
Journal:  CMAJ       Date:  1990-07-01       Impact factor: 8.262

2.  Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

Authors:  L M Aledort; M W Hilgartner; M C Pike; G F Gjerset; M A Koerper; E Y Lian; J M Lusher; J W Mosley
Journal:  BMJ       Date:  1992-01-25

3.  Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates.

Authors:  Oliver T Stirrup; David T Dunn
Journal:  BMC Med Res Methodol       Date:  2018-06-27       Impact factor: 4.615

Review 4.  Oral complications of HIV disease.

Authors:  Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

5.  Modeling the effect of age on quantiles of the incubation period distribution of COVID-19.

Authors:  Xiaohui Liu; Liwen Wu; Lei Wang; Xiansi Ma; Jiewen Wang
Journal:  BMC Public Health       Date:  2021-09-27       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.